An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, announced participation in several upcoming investor conferences. Management will present at the Stifel 2022 Healthcare Conference in New York from November 15-16 and the Jefferies London Healthcare Conference from November 15-17. An Early R&D Day is scheduled for October 20, 2022, in New York, featuring updates on preclinical research from Chief Scientific Officer Paul Moore, PhD. Presentations will be accessible on Zymeworks' website.
Positive
None.
Negative
None.
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences:
Stifel 2022 Healthcare Conference. Zymeworks’ management will participate in one-on-one meetings and present on November 15th – 16th in New York, NY.
Jefferies London Healthcare Conference. Zymeworks’ management will participate in one-on-one meetings and present on November 15th – 17th in London, United Kingdom.
In addition, Zymeworks will present an update on its preclinical research programs at an Early R&D day on October 20th, 2022, in New York, NY. At this event, led by Paul Moore, PhD, Zymeworks’ Chief Scientific Officer, we plan to present data from multiple preclinical product candidates built upon our industry-leading multispecific and next-generation TOPO1i based ADC platforms as well as an update to our future scientific vision.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2 ‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
What conferences will Zymeworks participate in November 2022?
Zymeworks will participate in the Stifel 2022 Healthcare Conference in New York from November 15-16 and the Jefferies London Healthcare Conference from November 15-17.
What is the date of Zymeworks' Early R&D Day?
The Early R&D Day for Zymeworks is scheduled for October 20, 2022, in New York.
Who will present at the Early R&D Day for Zymeworks?
The Early R&D Day will be led by Paul Moore, PhD, Zymeworks' Chief Scientific Officer.
Where can I find Zymeworks' presentations and webcasts?
All presentations and webcasts will be available on Zymeworks' website at http://ir.zymeworks.com/events-and-presentations.
What are Zymeworks' lead clinical candidates?
Zymeworks' lead clinical candidates include zanidatamab, a HER2-targeted bispecific antibody, and zanidatamab zovodotin (ZW49), a HER2-targeted antibody-drug conjugate currently in Phase 1 clinical development.
